As a founding member of ERA, TAmiRNA positions itself as the innovative driving force behind RNA biomarker development in Europe — combining novel biomarker products with premier research services in cell-free RNA and EV/exosome analysis. Vienna, Austria — September 8, 2026 TAmiRNA is proud to announce that it has joined six other independent European RNA companies — Anemocyte, Genevia Technologies, Immagina Biotechnology, Lexogen, MultiplexDX, and siTOOLS Biotech — as a founding member of the European RNA Alliance (ERA), a new strategic alliance launched today to strengthen Europe's position in high-quality RNA technologies. RNA technologies are increasingly central to modern medicine — diagnostics, disease monitoring, prophylaxis, therapeutics, and personalized treatment. Yet Europe's considerable expertise in this space is [...]